GlassScriptPhysician profile
Adam C Lessne
NPI 1740504778
$54,712.45
in general payments reported to CMS, 2019-2025
40 companies · $46K in 2025
The $46K reported for 2025 was more than what 97% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $918 · 2020: $354 · 2021: $528 · 2022: $1,454 · 2023: $2,383 · 2024: $3,575 · 2025: $46K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Food and Beverage: $10K · Consulting Fee: $8,063 · Honoraria: $4,500 · Travel and Lodging: $1,233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,319.00 |
| Food and Beverage | $10,344.28 |
| Consulting Fee | $8,062.50 |
| Honoraria | $4,500.00 |
| Travel and Lodging | $1,232.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $29,285.05 | 2025 | Rezdiffra |
| Genzyme Corporation | $9,105.46 | 2022-2025 | |
| Qol Medical, LLC | $6,236.88 | 2021-2025 | Sucraid, Sucraid |
| Abbvie INC. | $2,072.19 | 2019-2025 | |
| Janssen Biotech, INC. | $1,374.51 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $952.10 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Phathom Pharmaceuticals, INC. | $676.41 | 2024-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $608.16 | 2022-2025 | Rebyota, Clenpiq |
| Takeda Pharmaceuticals U.S.A., INC. | $574.80 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Medtronic, INC. | $568.12 | 2021-2024 | Endoflip |
| Celgene Corporation | $456.09 | 2022-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $386.48 | 2019-2025 | Ocaliva |
| Lilly USA, LLC | $317.41 | 2023-2025 | Omvoh |
| Gilead Sciences, INC. | $302.69 | 2019-2025 | |
| Ardelyx, INC. | $182.55 | 2022-2025 | Ibsrela |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $173.92 | 2024 | Vegzelma |
| Braintree Laboratories, INC. | $146.09 | 2019-2025 | Sutab, Suflave |
| Ethicon US, LLC | $127.89 | 2023 | Linx Reflux Management System |
| Aimmune Therapeutics, INC. | $120.00 | 2024-2025 | Zenpep |
| Boston Scientific Corporation | $111.38 | 2019 | |
| Redhill Biopharma INC. | $100.55 | 2021-2023 | Talicia, Aemcolo, Movantik |
| Merck Sharp & Dohme LLC | $97.53 | 2019-2024 | Dificid |
| Regeneron Healthcare Solutions, INC. | $90.42 | 2023-2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $85.75 | 2024 | Iqirvo |
| Shionogi INC | $70.79 | 2019-2020 | |
| Evoke Pharma, INC. | $58.66 | 2023-2024 | Gimoti |
| Pfizer INC. | $50.60 | 2024 | |
| Vivus LLC | $49.67 | 2021-2025 | Pancreaze |
| Novo Nordisk INC | $43.85 | 2025 | Wegovy |
| Nestle Healthcare Nutrition INC. | $39.91 | 2021 | |
| Endo Pharmaceuticals INC. | $33.18 | 2019-2022 | |
| Daiichi Sankyo INC. | $32.42 | 2019 | |
| Amgen INC. | $30.18 | 2021 | |
| Pharmacosmos Therapeutics INC. | $24.66 | 2023 | Monoferric |
| Allergan, INC. | $22.76 | 2019 | |
| Janssen Scientific Affairs, LLC | $22.08 | 2025 | Tremfya |
| Exact Sciences Corporation | $21.81 | 2025 | The Cologuard Plus Collection Kit |
| Alfasigma USA, INC. | $21.40 | 2020 | |
| Mahana Therapeutics, INC. | $20.98 | 2022 | |
| Ironwood Pharmaceuticals, INC | $17.07 | 2023 | Linzess |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Lessne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.